ClinicalTrials.gg
RecruitingNCT06444815STEALTH-001Updated Nov 17, 2026

A Study of VET3-TGI in Patients With Solid Tumors

A Phase 1 interventional study of VET3-TGI and Atezolizumab in Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer and Head and Neck Squamous Cell Carcinoma, sponsored by KaliVir Immunotherapeutics. Recruiting at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by KaliVir Immunotherapeutics · Phase 1, Interventional, and Treatment

How we know · 13 judgments

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.
Updated Nov 17, 2026Site recruiting status changedStudy contact changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States — 213 open to participants now, 347 under way, 28 of them phase 3. Squamous Cell Carcinoma of Head and Neck · United States.

Planned enrollment
377th of 994
60 · median 41
Started
2024
with 64 others
Phase 1
362 of 1,099
70 open now
Primary completion
2027-09
later than 167 of 346 live
Registered
963rd of 1,099
by date

Among the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, this one is the 377th largest by planned enrollment of the 994 interventional ones that give a count, is one of 65 that started in 2024, is one of 362 in phase 1, reaches primary completion later than 167 of the 346 other live ones, and was the 963rd registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

213 of the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States are open now. Recruiting first, the newest first:

208 more — sign in →

All 213 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, or all of them as a file.
02

Study summary

VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by direct injection into tumor(s) (called an intratumoral injection) or when given intravenously (into the vein) both alone and in combination with atezolizumab in patients with solid tumors (STEALTH-001).

Read the detailed description

VET3-TGI was changed in a laboratory to infect and kill cancer cells, leaving healthy cells alone. This is a Phase 1 dose escalation (and expansion) study with VET3-TGI administered by direct injection into tumor(s) or by intravenous infusion. The dose escalation has 4 groups: the first group (Group A) will determine the highest tolerated dose of VET3-TGI when injected into tumor(s); the second group (Group C) will determine the highest tolerated dose of VET3-TGI when infused into the vein. The third and fourth groups (Group B and D) will combine VET3-TGI with atezolizumab. These groups will begin at the highest tolerated dose determined in Group B and Group D, respectively.

Once the highest tolerated dose is found for each of these groups, that dose may be expanded to up to 15 additional patients to better examine the efficacy of VET3-TGI.

03

Conditions studied

  • Solid Tumor, Adult
  • Microsatellite Stable Colorectal Cancer
  • Head and Neck Squamous Cell Carcinoma
  • Cervical Cancer
  • Kidney Cancer
  • Renal Cell Carcinoma
  • Melanoma Stage IV
  • Merkel Cell Carcinoma of Skin
  • Mesothelioma
  • Non-small Cell Lung Cancer
  • Cutaneous Squamous Cell Carcinoma (CSCC)
  • Urothelial Carcinoma Bladder
  • Squamous Cell Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Have confirmed, advanced, unresectable, or solid tumors. Preferred indications include, but are not limited to, breast carcinoma, bladder carcinoma, cervical squamous carcinoma, colorectal carcinoma, esophageal carcinoma, head and neck squamous carcinoma, renal cell carcinoma, ovarian carcinoma, sarcoma, thymoma, and uterine carcinoma.
  • Failed, intolerant to, or refused potentially curative treatment options, including but not limited to, standard of care molecularly targeted agents, immunotherapy (e.g., anti -pembrolizumab/PDL1 antibodies), and chemotherapy
  • as per 1.1 criteria
  • At least one tumor amenable to safe ITu injections and/or
  • performance status 0 or 1
  • Demonstrate adequate organ function
  • Must be willing to comply with all protocol procedures and adhere to post-treatment care instructions

Additional Inclusion criteria exist

Key Exclusion Criteria:

  • Prior systemic therapy washout (dependent upon the therapy)
  • Requires use of anti- or anti-coagulant therapy that cannot be safely suspended for per protocol biopsies or intra-tumoral injections.
  • and/or carcinomatous meningitis that have not been completely resected or completely irradiated.
  • Prior history of myocarditis
  • Known /AIDS, active or infection.
  • Receiving high dose medication or has a significant immunodeficiency (e.g. transplant recipient, etc).

Additional Exclusion criteria exist

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Group A: VET3-TGI alone intratumoral

    Dose escalation of VET3-TGI alone administered by direct injection into tumor(s) x 4. Booster injections of VET3-TGI are permitted for up to 2 years.

    Drug: VET3-TGI

  • Experimental
    Group B: VET3-TGI intratumoral in combination with atezolizumab

    VET3-TGI will be given in combination with atezolizumab at the highest tolerated dose from Group A. Atezolizumab will be administered via intravenous (IV) infusion for up to 2 years.

    Drug: VET3-TGI · Drug: Atezolizumab

  • Experimental
    Group C: VET3-TGI alone intravenous

    Dose escalation of VET3-TGI alone administered by IV infusion x 6. Booster infusions of VET3-TGI are permitted for up to 2 years.

    Drug: VET3-TGI

  • Experimental
    Group D: VET3-TGI intravenous in combination with atezolizumab

    VET3-TGI will be given in combination with atezolizumab at the highest tolerated dose from Group C. Atezolizumab will be administered via intravenous (IV) infusion for up to 2 years.

    Drug: VET3-TGI · Drug: Atezolizumab

Interventions

  • DrugVET3-TGI

    Oncolytic vaccinia virus engineered with immunomodulatory transgenes

  • anti-pd-L1 antibody

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events with VET3-TGI alone or in combination with atezolizumab

    Percentage of patients with adverse events by grade as determined by NCI CTCAE v5.0

    Time frame: 108 months

  2. Incidence of dose limiting toxicities reported with VET3-TGI alone or in combination with atezolizumab

    Number of dose limiting toxicities, as defined in the protocol, by dose group

    Time frame: 4 weeks

  3. Determine the recommended Phase 2 dose

    he highest dose of VET3-TGI in each group that can be administered where fewer than 2 patients have a dose-limiting safety event alone or when combined with atezolizumab as assessed by NCI CTCAE v.5.0 during the Phase 1 dose escalation

    Time frame: 4 weeks

Secondary outcomes

  1. Efficacy assessment: overall response rate (ORR)

    The number and proportion of patients with a partial response (PR) or complete response (CR) on imaging by RECIST 1.1

    Time frame: 108 months

  2. Efficacy assessment: Duration of response (DOR)

    Median duration of response in patients with a CR or PR

    Time frame: 108 months

  3. Efficacy assessment: disease control rate (DCR)

    The number and proportion of patients with stable disease (SD), or a partial response (PR) or complete response (CR) on imaging by RECIST 1.1

    Time frame: 108 months

  4. Efficacy assessment: Time to tumor progression (TTP)

    Median time until patient disease progression (PD)

    Time frame: 108 months

  5. Efficacy assessment: Progression free survival (PFS)

    Median duration of progression free survival of subjects

    Time frame: 108 months

  6. Overall survival

    median duration of survival across all subjects

    Time frame: 108 months

  7. Immune changes in tissue and blood

    number of subject tissue samples with immune cell infiltrates and heat map changes in the molecular signature of tissue samples

    Time frame: 6 weeks

  8. VET3-TGI delivery and replication kinetics

    Number of subject tissues with positive VET3-TGI gene signatures denoting delivery and complete replication of VET3-TGI

    Time frame: 6 weeks

07

Study locations

7 of 8 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Data is aggregated.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Sep 2027, 36 months after the start.

Of 156 industry-sponsored phase 1 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 72. This study's planned 36 months is below that.

Counting every sponsor, half of 272 studies reached it within 49 months; a quarter within 33 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2024
First posted
Jun 6, 2024
StartActual
Sep 16, 2024
Primary completionEst.
Sep 30, 2027
CompletionEst.
Dec 31, 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 1 site removed. Community Health Network is now Active, not recruiting
Show 2 added (2 United States)
  • Mary Crowley Cancer Research/Sarah Cannon Research Institute · Dallas, United States
  • University of Washington, Fred Hutchinson Cancer Center · Seattle, United States
Show 1 removed
  • Mary Crowley Cancer Research · Dallas, United States
Nov 17, 2026
Contact
Study contact's phone or email changed: •••2084→•••6732. See the current contact
Nov 17, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • USC/Norris Comprehensive Cancer Center · Los Angeles, United StatesContact X•••@med.usc.edu→c•••@kalivir.com
  • Community Health Network · Indianapolis, United StatesContact removed •••2627Contact removed (no phone or email listed)
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    2 sites added, 1 site removed. Community Health Network is now Active, not recruiting
    Show 2 added (2 United States)
    • Mary Crowley Cancer Research/Sarah Cannon Research Institute · Dallas, United States
    • University of Washington, Fred Hutchinson Cancer Center · Seattle, United States
    Show 1 removed
    • Mary Crowley Cancer Research · Dallas, United States
    Contact Study contact's phone or email changed: •••2084→•••6732. See the current contact
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • USC/Norris Comprehensive Cancer Center · Los Angeles, United StatesContact X•••@med.usc.edu→c•••@kalivir.com
    • Community Health Network · Indianapolis, United StatesContact removed •••2627Contact removed (no phone or email listed)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06444815
Lead sponsor
KaliVir Immunotherapeutics
Responsible party
Sponsor
First posted
Jun 6, 2024
Start date
Sep 16, 2024
Primary completion
Sep 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Adina Pelusio
Contact
clinops@kalivir.com
+1-412-435-6732
James Burke, MD
Contact
clinops@kalivir.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion